Summary of the Conference Call for Dize Pharmaceutical Company Overview - **Company**: Dize Pharmaceutical - **Key Products**: Shuorze (舒尔哲), 8,586, 6,008, and Grixotin (格力西替尼) Industry Insights - **FDA Approvals**: Shuorze received accelerated approval from the FDA, becoming the first oral EGFR TKI for small cell lung cancer with an insertion of easy-to-interact factor 20, gaining significant market advantage [2][3] - **Market Position**: 8,586 is the first dual-pathway BTK inhibitor globally, showcasing promising results in CLL and SLL treatments at the ASCO conference [2][3] Financial Performance - **Revenue Growth**: In the first half of 2025, Dize Pharmaceutical's revenue increased by 74% year-on-year to 355 million RMB, with a sales expense ratio reduction of approximately 24% [2][5] - **Cash Reserves**: The company successfully raised nearly 1.8 billion RMB through refinancing, increasing cash reserves to 2.251 billion RMB, alleviating investor concerns about cash flow [2][6] Key Milestones - **Shuorze Developments**: - Approved by the FDA in July 2025 and included in the NCCN guidelines shortly after [3][7] - Ongoing Phase III registration studies to meet FDA requirements [8] - **8,586 Developments**: - Demonstrated significant efficacy in DLBCL patients, with an objective response rate (ORR) of 84.2% in frontline treatment failure patients [16] - Fast track designation from the FDA based on clinical results [18] - **6,008 Developments**: - Showed significant effects on resistant EGFR mutations, with over 50 times selectivity against wild-type EGFR [19] - Currently progressing towards registration clinical trials with over 100 patients enrolled [30] Research and Development - **Pipeline Projects**: - GW5,282 is in the dose escalation phase, showing potential in both hematological and solid tumors [23][25] - Grixotin is undergoing multiple Phase II clinical trials to determine first-line treatment strategies [24][32] - **Clinical Trials**: - Multiple Phase III trials are set to begin or are already underway, with expectations for positive results to enhance investor returns [33] Strategic Focus - **Market Strategy**: The company emphasizes maximizing product value through strategic partnerships rather than merely pursuing business development [22] - **Future Directions**: Dize Pharmaceutical aims to explore new targets and non-oncological indications while ensuring existing product lines are fully developed [26] Conclusion - Dize Pharmaceutical is positioned for significant growth with its innovative drug pipeline, strong financial performance, and strategic market positioning, indicating a promising outlook for investors and stakeholders in the pharmaceutical industry.

Core Viewpoint - The report highlights the financial performance and operational challenges faced by InventisBio, emphasizing its ongoing drug development efforts and the risks associated with being a pre-revenue biotech company [1][3][4]. Financial Performance - The company reported a revenue of 19.16 million RMB for the first half of 2025, representing a 28.85% increase compared to 14.87 million RMB in the same period last year [3]. - The total profit for the period was a loss of 119.43 million RMB, an improvement from a loss of 214.22 million RMB in the previous year [3]. - The net assets attributable to shareholders decreased by 5.12% to 171.81 million RMB from 181.08 million RMB at the end of the previous year [3]. Research and Development Focus - InventisBio is focused on developing innovative drugs targeting major diseases such as cancer, metabolic disorders, and autoimmune diseases, with a commitment to addressing unmet clinical needs [5][19]. - The company has established various platforms for drug discovery and development, including target evaluation, molecular design, pharmacology, and clinical trial design [5][19]. - All products in the pipeline are self-developed, with global intellectual property rights, and collaborations with well-known pharmaceutical companies [7][19]. Product Pipeline - The company has two authorized products: - **Befotertinib (BPI-D0316)**: An EGFR tyrosine kinase inhibitor for treating EGFR mutation-positive non-small cell lung cancer (NSCLC) [8][9]. - **Gisoresib (D-1553)**: A KRAS G12C inhibitor for treating various cancers, including NSCLC and colorectal cancer, with ongoing international clinical trials [9][10]. - Other products in clinical trials include: - **Taragarestrant (D-0502)**: An oral selective estrogen receptor degrader for ER-positive, HER2-negative breast cancer [12][16]. - **D-0120**: A URAT1 inhibitor for treating hyperuricemia and gout, showing promising results in clinical trials [14][19]. - **D-2570**: A selective TYK2 inhibitor for treating psoriasis and other autoimmune diseases, with favorable safety and efficacy profiles [16][19]. Market Position and Strategy - The company aims to enhance its market position and international competitiveness by focusing on innovative drug development and addressing significant clinical needs [5][19]. - InventisBio's operational model involves outsourcing non-core activities to third-party service providers while maintaining control over critical research and development processes [19].

Group 1 - The core index of the Sci-Tech Innovation Board, the Sci-Tech 50 Index, surged nearly 6% to surpass 1200 points, reaching a new high in over three years [1] - Among the constituent stocks, Yuntian Lifei and Pinggao Co. hit the 20% daily limit, while Haiguang Information and Shengmei Shanghai rose over 17%, and Cambrian Technology increased by over 13% [2] - According to Zheshang Securities, nearly half of the companies represented by the Sci-Tech 100 and Sci-Tech 200 indices are showing signs of reversal as of Q1 2025, indicating a bottoming out of profits for larger market cap companies [2] Group 2 - The analysis draws parallels to the bull market in the ChiNext board from 2013 to 2015, which was divided into three phases: expectation-driven, industry prosperity-driven, and capital sentiment-driven [2] - The main upward phase of the current market is expected to be driven by improvements in AI and innovative pharmaceuticals, with the Sci-Tech Board entering its main upward phase since June of this year [2] - Current fund allocation levels indicate that the Sci-Tech Board is at a similar configuration level to the early stages of the ChiNext bull market, suggesting potential for further upward movement [2]

Group 1: Company Research - Yiyu Shikong has made significant progress in automotive and dye LCD materials, photoresist resin, PSPI business, and OLED materials, with automotive LCD materials entering mass production and expected to generate tens of millions in revenue by H2 2025 [1] - ST Chengchang has seen a recovery in downstream user demand, with a notable increase in orders and projects, particularly in satellite and low-orbit satellite fields, which are expected to become new growth points [1] - Jibite has focused on user-driven innovation in game development, with successful titles like "Zhang Jian Chuan Shuo" and "Dao You Lai Wa Bao," while also adjusting its business focus and optimizing personnel configuration [2] - Huadong Pharmaceutical has made significant advancements in innovative drug development across various fields, with multiple products entering clinical stages and a growing revenue share from innovative drugs [3] Group 2: Market Insights - The automotive LCD materials market is expected to grow significantly, with Yiyu Shikong's production capacity reaching 200 tons annually and a focus on new customer development [1] - The low-orbit satellite sector is projected to see substantial growth, with ST Chengchang leveraging its technological advantages to meet increasing demand [1] - The gaming industry is experiencing diverse demand and intense competition, prompting companies like Jibite to focus on user needs and innovative gameplay [2] - The innovative drug market is expanding, with Huadong Pharmaceutical's innovative drug business revenue approaching 15% of total revenue in H1 [3] Group 3: Financial Performance - Silver华基金 has an asset management scale of 576.925 billion, ranking 22nd among 210 firms, with a notable performance from its Hong Kong Stock Connect Innovation Drug ETF, which grew by 123.18% in the past year [4]

Company Overview - Haichuang Pharmaceutical-U's stock price is reported at 61.39 yuan, down 1.08% from the previous trading day, with a trading volume of 1.44 billion yuan [1] - The company operates in the biopharmaceutical sector, focusing on innovative drug development, particularly utilizing PROTAC technology and deuterated technology [1] Financial Performance - For the first half of 2025, the company reported revenue of 13.17 million yuan, representing a significant year-on-year increase of 11,899.08%, primarily driven by the approval and sales of its first Class 1 new drug, deuterated enzalutamide soft capsules, which generated sales revenue of 13.07 million yuan [1] Market Activity - On August 21, the company experienced a net outflow of 5.73 million yuan in principal funds, with a cumulative net outflow of 9.66 million yuan over the past five days [1]

Group 1 - The stock price of Kangchen Pharmaceutical is reported at 53.57 yuan, down by 0.42 yuan or 0.78% from the previous trading day [1] - The stock reached a high of 55.09 yuan and a low of 53.34 yuan during the trading session, with a total transaction volume of 1.87 billion yuan [1] - Kangchen Pharmaceutical operates in the biopharmaceutical sector, focusing on the research and development of innovative drugs [1] Group 2 - The company has recently completed the enrollment of the first subject in the Phase I clinical trial for its self-developed drug KC1086, which is a small molecule inhibitor of lysine acetyltransferase 6, intended for the treatment of advanced solid tumors [1] - On August 21, the net inflow of main funds was 54.18 million yuan, while the net outflow over the past five days amounted to 1.48 billion yuan [1]

Group 1 - The core viewpoint is that southbound funds have become a crucial driving force in the Hong Kong stock market, with their influence expected to deepen due to unique investment opportunities and long-term policy support [1][2] - Southbound funds account for over one-third of the daily turnover on the Hong Kong Stock Exchange and hold nearly 15% of the free float market capitalization, with both metrics showing over 30% growth compared to before 2024 [2] - Cumulative net inflows from southbound funds have reached $14 billion since 2025, surpassing the total for 2024, with daily inflows increasing by 84.6% year-on-year [2] Group 2 - Historically, stocks included in the southbound trading scheme show strong performance prior to inclusion, with an average increase of 3.7% in the 30 days before inclusion, outperforming the Hang Seng Index by 5.2% [3] - In February, 26 out of 27 stocks that were included in the southbound scheme saw price increases in the 30 days prior, with an average absolute return of 41% [3] - Post-inclusion, stocks may experience short-term pressure, with an average relative return of -2.0% against the Hang Seng Index in the following 30 days, but a long-term excess return of 4.6% over 90 days [3] Group 3 - Morgan Stanley has developed a southbound stock selection model (MSSBT) that accurately predicts stocks to be included, achieving an average hit rate of 85% across the last four semi-annual inclusion cycles [4] - The model's hit rate reached 97% in the August 2024 cycle, with a simulated portfolio showing an average absolute return of 10.1% in the 30 days prior to inclusion [4] - The model employs strict selection criteria, including market capitalization above HKD 50 billion and compliance with turnover standards, while excluding stocks with high ownership concentration [4] Group 4 - In September, 19 stocks are predicted to be included in the southbound trading scheme, with a focus on the healthcare (6 stocks) and industrial (5 stocks) sectors, indicating increased interest in innovative drug development and high-end manufacturing [5][6] - The top five candidates by market capitalization include Cao Cao Inc (02643), Yimeng Biotech (09606), Nanshan Aluminum International (02610), Zhengli New Energy (03677), and Yunzhisheng (09678) [6] Group 5 - The recommended strategy for maximizing returns includes entering positions one month prior to inclusion, diversifying with equal-weighted stock selections, and selling on the official inclusion date to lock in short-term gains [8]

Group 1 - The core viewpoint is that southbound funds have become a crucial driving force in the Hong Kong stock market, with their influence expected to deepen due to unique investment opportunities and long-term policy support [1][2] - Southbound funds account for over one-third of the daily net inflow in the Hong Kong Stock Exchange's main board trading volume and hold nearly 15% of the free float market capitalization of Hong Kong stocks, both metrics having increased by over 30% since before 2024 [2] - Cumulative net inflow from southbound funds has reached $14 billion since 2025, surpassing the total for 2024, with daily inflows increasing by 84.6% year-on-year [2] Group 2 - Stocks included in the southbound trading scheme typically show strong performance prior to inclusion, with an average increase of 3.7% in the 30 days before inclusion, outperforming the Hang Seng Index by 5.2% [3] - In February, 26 out of 27 stocks included in the southbound scheme rose in the 30 days prior, with an average absolute return of 41% and a relative return of 19% compared to the Hang Seng Index [3] - Post-inclusion, stocks may experience short-term pressure, with an average relative return of -2.0% over 30 days, but still show a long-term excess return of 4.6% over 90 days [3] Group 3 - Morgan Stanley has developed a southbound stock selection model (MSSBT) that accurately predicts stocks to be included in the scheme, achieving an average hit rate of 85% across the last four semi-annual inclusion cycles, with a peak of 97% in August 2024 [4] - The simulated portfolio under equal-weight allocation shows an average absolute return of 10.1% in the 30 days prior to inclusion, outperforming the Hang Seng Index by 7.4% [4] - The model employs strict selection criteria, including market capitalization above 50 billion HKD and compliance with turnover rate standards, while excluding stocks with high ownership concentration [4] Group 4 - The latest forecast indicates that 19 stocks will be included in the southbound scheme in September, covering seven major sectors, with healthcare (6 stocks) and industrials (5 stocks) making up over 50% of the list [5][6] - The top five candidates by market capitalization include Cao Cao Inc (Industrials), Ying En Biological (Healthcare), Nanshan Aluminum International (Materials), Zhengli New Energy (Industrials), and Yunzhisheng (Information Technology) [6] Group 5 - The recommended strategy for maximizing returns involves entering positions one month prior to inclusion, diversifying risk through equal-weight allocation of selected stocks, and locking in short-term gains by selling on the official inclusion date [8]

Group 1 - The Chinese government emphasizes the importance of accelerating the development of the biopharmaceutical industry, focusing on high-quality technological supply and policy support to enhance innovation and produce more effective drugs [1][2] - The government aims to strengthen original innovation and tackle key core technologies, leveraging both government and market resources to foster a collaborative innovation environment [2] - There is a significant market potential for the health industry in China, with a strong emphasis on the development of innovative drugs and the need for timely identification of high clinical value projects [1][2] Group 2 - The government encourages the establishment of comprehensive support systems for biopharmaceutical innovation, including one-stop R&D solutions and collaboration between industry, academia, and research [2] - The integration of artificial intelligence in various stages of drug development, clinical trials, and production is highlighted as a means to enhance industry development [2] - The government also aims to promote the modernization and industrialization of traditional Chinese medicine by applying modern scientific theories and technologies [2]

Core Viewpoint - As of August 18, 2023, AAPG's stock price increased by 5.35%, reaching $47.4 per share, with a total market capitalization of $4.406 billion. The company reported a total revenue of 981 million RMB for the year ending December 31, 2024, representing a year-on-year growth of 341.77%, while the net profit attributable to shareholders was -405 million RMB, showing a year-on-year increase of 56.2% [1]. Financial Performance - AAPG's total revenue for the fiscal year ending December 31, 2024, is projected to be 981 million RMB, reflecting a significant year-on-year growth of 341.77% [1]. - The net profit attributable to shareholders is expected to be -405 million RMB, which indicates a year-on-year increase of 56.2% [1]. Upcoming Events - AAPG is scheduled to disclose its mid-year report for the fiscal year 2025 on August 20, 2023, after the market closes (Eastern Time) [2]. Company Overview - AAPG is a biopharmaceutical company based in China, focusing on developing innovative drugs for cancer, hepatitis B, and age-related diseases. The company was listed on the Hong Kong Stock Exchange on October 28, 2019, under the stock code 6855.HK [3]. - AAPG has established a proprietary drug design platform targeting protein-protein interactions and is at the forefront of developing new drugs in the apoptosis pathway. The company has a pipeline of nine clinical-stage Class 1 small molecule drugs, including inhibitors targeting key proteins in the apoptosis pathway [3]. - The core product, Olarebatin (brand name: Nairike), has been approved in China and is included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2022). It has also received various designations from the FDA and the EU [3]. - AAPG has engaged in over 40 clinical trials across China, the U.S., Australia, and Europe, and has established collaborations with leading biotech and pharmaceutical companies and academic institutions globally [3].